# Sanofi share price today (Sanofi, SNY)

> Sanofi's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SNY · Healthcare · Drug Manufacturers - General · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/sny

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $45.33 (−10.4% in a year)
- P/E: 23.4×, against its own history
- Revenue (Jun 2026): EUR 12.3 B (+14.6% on a year ago)
- Profit (Jun 2026): EUR 377 M (−90.4% on a year ago)
- Operating margin: 21.0% (+5.1 points on a year ago)
- ROE: 11%, FY25
- ROIC: 9.0%, against a 5.2% cost of capital: +3.8 points
- Profit that came in as cash: 159%, last 3 years

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Sanofi share price today? Sanofi's share price was $45.33 at the close on 3 November 2026. It has been stalling near its high for 2 weeks. That is 2.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $40 and $52, and at that close it sat 44% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved +11% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Sanofi pay? Sanofi declared EUR 4.12 per local share for Dec 2025. It reports in euros, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield. ## Which stock lists is Sanofi on? Sanofi is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Sanofi profitable? Sanofi earned EUR 377 M of net profit in the Jun 2026 quarter, −90.4% on the same quarter a year earlier. Full-year FY25 profit was EUR 7.9 B. Over 4 years profit has grown 5.7% a year on average. That is 3.1% of the quarter's revenue. The same quarter a year earlier earned EUR 3.9 B. 1 of the last 11 reported quarters were loss-making. For the full year, FY25 profit was EUR 7.9 B (+39.7% on the year before). Why profit moved: revenue changed +14.6% on a year earlier and the margin moved +5.1 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −35.4% and revenue +4.5%. Profit is growing slower than sales: rising costs are taking part of the growth. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## How much revenue does Sanofi make, and is it growing? Sanofi reported EUR 12.3 B of revenue in the Jun 2026 quarter, +14.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 4.5% a year on average. The last full year, FY25, came in at EUR 46.7 B. The last four reported quarters add to EUR 48.9 B. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was EUR 46.7 B, +5.5% on the year before. Recent pace: the last four quarters grew +4.5% on average, against 4.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## How much of its sales does Sanofi keep? Sanofi's operating margin was 21.0% in the Jun 2026 quarter, 5.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 19.8% and 25.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +5.1 percentage points on the year while gross margin changed +4.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Sanofi's profit turning into cash? Over the last 3 years, 159% of Sanofi's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in EUR 10.8 B of operating cash against EUR 7.9 B of profit. After EUR 1.8 B of spending on assets, EUR 9.0 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## Where does Sanofi's cash go? Sanofi does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent EUR 5.1 B on assets over the last 3 years. Averaged over those years that is 3.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: EUR 5.1 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## What is Sanofi's P/E ratio, and how does it compare with its own history? Sanofi's P/E is 23.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Sanofi business getting better or worse? Sanofi's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sanofi earn on its capital? Sanofi earned a ROE of 11% in FY25. That is up from a low of 7% in FY24. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.8% net margin and 0.37× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 16.8% net margin × 0.37× asset turnover × 1.77× leverage (assets divided by equity) ≈ 11.0% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.0% − 5.2% = +3.8 percentage points. The 5.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Sanofi have too much debt? Sanofi has total debt of EUR 23.6 B against shareholder equity of EUR 69.6 B as of Jun 2026, so its debt is 0.34× its equity. Year by year, that ratio went from 0.32 in FY21 to 0.28 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## What is the Sanofi shareholding pattern? 1.1% of Sanofi's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 3.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Sanofi from balance-sheet trouble? For Sanofi, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sanofi rank in its industry? 49.7 out of 100, rank 8 of 16 in Drug Manufacturers - General, with 66% of the evidence available. Sanofi scores 49.7 out of 100 against the 16 companies it is compared with in Drug Manufacturers - General, ranking 8. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 20.6 + 9.2 + 14.5 + 5.4 = 49.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sanofi compared with? Sanofi ranks 8 of 16 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 49.7 out of 100. 1. [Eli Lilly and Company](https://www.sectoralpha.in/us/stocks/lly) LLY · turning · Sector-leading setup · 85% evidence 83.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.0/35 · Revenue 45.5% · Profit 49.8% · Operating margin change 5.4 points · 95% evidence Capital efficiency 21.4/25 · ROCE 41.7% · Operating margin 53.7% · 76% evidence Valuation 11.9/20 · P/E 37.4× · PEG 0.74 · 65% evidence Relative strength 18.4/20 · Lead over its industry 15.6% · Lead over S&P 500 23.1% · 1 year 52.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 32 + 21.4 + 11.9 + 18.4 = 83.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [AbbVie Inc.](https://www.sectoralpha.in/us/stocks/abbv) ABBV · breaking out · Most evidence points up · 85% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.8/35 · Revenue 10.7% · Profit 100% · Operating margin change 1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 24.5% · Operating margin 37.3% · 76% evidence Valuation 4.4/20 · P/E 44.8× · PEG 2.67 · 65% evidence Relative strength 16.4/20 · Lead over its industry 8.4% · Lead over S&P 500 15.4% · 1 year 30.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.8 + 19.4 + 4.4 + 16.4 = 69 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) AMGN · leader · Most evidence points up · 81% evidence 67.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 9.1% · Profit 32.1% · Operating margin change 2.9 points · 83% evidence Capital efficiency 15.2/25 · ROCE 18.2% · Operating margin 35.5% · 76% evidence Valuation 13.1/20 · P/E 22.4× · PEG 0.71 · 65% evidence Relative strength 15.4/20 · Lead over its industry 12.1% · Lead over S&P 500 19.3% · 1 year 44.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.2 + 15.2 + 13.1 + 15.4 = 67.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Gilead Sciences, Inc.](https://www.sectoralpha.in/us/stocks/gild) GILD · leader · Evidence leans up · 75% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit -147.6% · Operating margin change -1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 30.3% · Operating margin 43.4% · 76% evidence Valuation 11.5/20 · P/E -47.8× · PEG n/a · 15% evidence Relative strength 17.6/20 · Lead over its industry 9.1% · Lead over S&P 500 16% · 1 year 40.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.6 + 19.4 + 11.5 + 17.6 = 63.1 · What this means: Relative strength against the index is 16%, and revenue and profit growth are weak. 5. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) GSK · basing · Evidence leans up · 81% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 5% · Profit 32.1% · Operating margin change 0.9 points · 83% evidence Capital efficiency 19.8/25 · ROCE 25.1% · Operating margin 30.9% · 76% evidence Valuation 14.5/20 · P/E 16.4× · PEG 0.39 · 65% evidence Relative strength 0.9/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.3% · 1 year 4.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 19.8 + 14.5 + 0.9 = 60.2 · What this means: Earnings are strong; relative strength in its sector is -15.7% and the one-year return is 4.4%. 6. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) BMY · quiet · Evidence leans up · 81% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 3.1% · Profit 83.8% · Operating margin change 0.7 points · 83% evidence Capital efficiency 18.1/25 · ROCE 22.7% · Operating margin 34.4% · 76% evidence Valuation 14.3/20 · P/E 12.7× · PEG 0.5 · 65% evidence Relative strength 4.0/20 · Lead over its industry -5.7% · Lead over S&P 500 0.4% · 1 year 32.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.6 + 18.1 + 14.3 + 4 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) AZN · turning · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 7.3% · Profit 17.4% · Operating margin change 3 points · 95% evidence Capital efficiency 14.2/25 · ROCE 17.6% · Operating margin 27.1% · 76% evidence Valuation 10.0/20 · P/E 22.9× · PEG 1.33 · 65% evidence Relative strength 7.3/20 · Lead over its industry -9.4% · Lead over S&P 500 -3.6% · 1 year 10.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.2 + 14.2 + 10 + 7.3 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. Sanofi this page SNY · turning · Evidence leans down · 66% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue n/a · Profit n/a · Operating margin change 5.1 points · 39% evidence Capital efficiency 9.2/25 · ROCE 10.7% · Operating margin 21% · 76% evidence Valuation 14.5/20 · P/E 22.8× · PEG 0.33 · 65% evidence Relative strength 5.4/20 · Lead over its industry -10.8% · Lead over S&P 500 -5% · 1 year -8.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 9.2 + 14.5 + 5.4 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) OGN · turning · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.3/35 · Revenue -2.5% · Profit -70.1% · Operating margin change -0.9 points · 83% evidence Capital efficiency 10.8/25 · ROCE 11.5% · Operating margin 20.7% · 76% evidence Valuation 15.5/20 · P/E 17× · PEG 0.17 · 65% evidence Relative strength 13.9/20 · Lead over its industry 15.2% · Lead over S&P 500 23% · 1 year 104.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9.3 + 10.8 + 15.5 + 13.9 = 49.5 · What this means: Relative strength against the index is 23%, and revenue and profit growth are weak. 10. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) BIIB · breaking out · Evidence leans down · 81% evidence 46.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.9/35 · Revenue 0.3% · Profit -45.4% · Operating margin change -9.2 points · 83% evidence Capital efficiency 7.9/25 · ROCE 8.9% · Operating margin 25.1% · 76% evidence Valuation 13.3/20 · P/E 38.2× · PEG 0.38 · 65% evidence Relative strength 17.5/20 · Lead over its industry 12.8% · Lead over S&P 500 20.1% · 1 year 60.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 7.9 + 7.9 + 13.3 + 17.5 = 46.6 · What this means: Relative strength against the index is 20.1%, and revenue and profit growth are weak. 11. [Johnson & Johnson](https://www.sectoralpha.in/us/stocks/jnj) JNJ · turning · Evidence leans down · 75% evidence 46.3 out of 100 Growth Capital Valuation Relative
12. [Novartis AG](https://www.sectoralpha.in/us/stocks/nvs) NVS · turning · Evidence leans down · 85% evidence 46.0 out of 100 Growth Capital Valuation Relative
13. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) PFE · leader · Evidence leans down · 71% evidence 44.5 out of 100 Growth Capital Valuation Relative
14. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) MRK · leader · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative
15. [Grifols, S.A.](https://www.sectoralpha.in/us/stocks/grfs) GRFS · turning · Evidence leans down · 71% evidence 41.3 out of 100 Growth Capital Valuation Relative
16. [Amarin Corporation plc](https://www.sectoralpha.in/us/stocks/amrn) AMRN · basing · Most evidence points down · 64% evidence 28.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - General](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general), all 16 compared on one page. ## Which companies are close to Sanofi in size? Sanofi is the 12th largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Novo Nordisk A/S, Pfizer Inc. and Bristol-Myers Squibb Company. Just below it: GSK plc, Biogen Inc. and Grifols, S.A. ### Drug Manufacturers - General companies close in size

1. [Novo Nordisk A/S](https://www.sectoralpha.in/us/stocks/nvo) $177.4 billion
2. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) $171 billion
3. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) $126.1 billion
4. Sanofi $108.1 billion
5. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) $97.4 billion
6. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) $36.8 billion
7. [Grifols, S.A.](https://www.sectoralpha.in/us/stocks/grfs) $7.6 billion

[All 17 Drug Manufacturers - General companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general#all-companies)

### Companies close in size in other industries

1. [Newmont Corporation](https://www.sectoralpha.in/us/stocks/nem) $113.4 billion · Gold
2. [CVS Health Corporation](https://www.sectoralpha.in/us/stocks/cvs) $113.2 billion · Healthcare Plans
3. Sanofi $111.2 billion
4. [Canadian Natural Resources Limited](https://www.sectoralpha.in/us/stocks/cnq) $110.8 billion · Oil & Gas Exploration & Production
5. [ServiceNow, Inc.](https://www.sectoralpha.in/us/stocks/now) $110 billion · Software - Application

## What else do people ask about Sanofi? ### What is Sanofi's stock price today? Sanofi's stock price is $45.33, −10.4% over the past year. The whole company is worth $108 B on the market. In the last 52 weeks it traded between $40 to $52; today it is 44% of the way up from the low, 2.3% above its 200-day average (as of 3 November 2026). ### What were Sanofi's latest quarterly results? Sanofi reported revenue of EUR 12.3 B and net profit of EUR 377 M for the Jun 2026 quarter. Revenue rose 14.6% and profit fell 90.4% compared with a year earlier. The operating margin was 21.0%, 5.1 percentage points higher than a year earlier (as of 3 November 2026). ### What is Sanofi's market cap? Sanofi's market capitalisation is $108 B at a stock price of $45.33. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sanofi performing? Sanofi's share price has been stalling near its high for 2 weeks. In its latest quarter, revenue rose 14.6% and profit fell 90.4% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 3 November 2026). ### Will Sanofi's stock price go up? This page does not forecast Sanofi's stock price. What it shows instead: the stock price is $45.33, and it has been stalling near its high for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Sanofi have too much debt? No, Sanofi has little debt: its debt is 0.27× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sanofi in its business cycle? Sanofi's FY25 operating margin was 20.7%, against a 5-year range of 19.8% to 25.8%: the low end of its own range, which is often where recoveries start. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sanofi story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sanofi a stock worth studying right now? What the numbers show: Sanofi's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.